09:12 EST Sana jumps 275% to $6.20 with diabetes data viewed as ‘best case’
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SANA:
- H.C. Wainwright ups Sana target after ‘best case scenario’ data
- Sana Biotechnology (NASDAQ:SANA) Soars 400% on Breakthrough Diabetes Transplant
- Sana Biotechnology upgraded to Buy from Hold at TD Cowen
- Closing Bell Movers: Cal-Maine Foods up 5% on Q2 results
- Sana Biotechnology up 285% afterhours following type 1 diabetes study data